ACM
MRNS

AIGH Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

AIGH Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,336,150
Closed -$9.22M – 59
2023
Q1 		$9.22M Buy
+1,336,150
New +$8.38M 3.4% 10

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

AIGH Capital Management's MRNS Position: Q2 2023 in Review

AIGH Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2023, closing a stake of 1,336,150 shares — an estimated $9.22M sold.

AIGH Capital Management first reported a position in MRNS in Q1 2023 and held it in 1 quarter. The position peaked at $9.22M in Q1 2023. 106 funds tracked by Wall St. Rank hold MRNS as of Q2 2023.

  • AIGH Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2023 after selling out during the quarter.
  • AIGH Capital Management sold 1,336,150 Marinus Pharmaceuticals, Inc shares in Q2 2023, an estimated $9.22M.
  • AIGH Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q1 2023 and held it in 1 quarter.
  • AIGH Capital Management's Marinus Pharmaceuticals, Inc position peaked at $9.22M in Q1 2023.
  • 106 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2023.

Based on AIGH Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.